Despite the efficacy advantage, CAIV-T will have to overcome its premium pricing and lingering safety concerns. Physicians may not be comfortable using a live vaccine in small children. |
What is news is that finally researchers have the actual genome, we have the data, but now the data is in widespread distribution. |